

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Examiner Signature	/Olga Chernyshev/	Date Considered	07/11/2007
-----------------------	-------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). * See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. * Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/525,726 (U.S. National Phase of PCT/EP03/09437)
				I.A. Filing Date	August 26, 2003
				First Named Inventor	Heinz VON DER KAMMER
				Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	1	of	3	Attorney Docket Number	2335.0060001/SRL/KPQ

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published	T ²	
/OC/	NPL1	Bertram, L., <i>et al.</i> , "Evidence for genetic linkage of Alzheimer's disease to chromosome 10q," <i>Science</i> 290:2302-2303, American Association for the Advancement of Science (2000)		
/OC/	NPL2	Cole, K.A., <i>et al.</i> , "cDNA Sequencing and Analysis of POV1 (PB39): A Novel Gene Up-regulated in Prostate Cancer," <i>Genomics</i> 51:282-287, Academic Press (1998)		
/OC/	NPL3	Li, M.-S., <i>et al.</i> , "Human eosinophil major basic protein, a mediator of allergic inflammation, is expressed by alternative splicing from two promoters," <i>Biochem. J.</i> 305:921-927, Portland Press (1995)		
/OC/	NPL4	Loring, J.F., <i>et al.</i> , "A Gene Expression Profile of Alzheimer's Disease," <i>DNA & Cell Biol.</i> 20:683-695, Mary Ann Liebert, Inc. (November 2001)		
/OC/	NPL5	Myers, A., <i>et al.</i> , "Susceptibility Locus for Alzheimer's Disease on Chromosome 10," <i>Science</i> 290:2304-2305, American Association for the Advancement of Science (2000)		
/OC/	NPL6	The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group, "Consensus Report of the Working Group on: Molecular and Biochemical Markers of Alzheimer's Disease," <i>Neurobiol. Of Aging</i> 9:109-116, Elsevier Science Inc. (1998)		
/OC/	NPL7	Roses, A.D., "Apolipoprotein E and Alzheimer's Disease," <i>Ann. N.Y. Acad. Sci.</i> 855:738-743, New York Academy of Sciences (1998)		
/OC/	NPL8	Scott, W.K., <i>et al.</i> , "Fine Mapping of the Chromosome 12 Late-Onset Alzheimer Disease Locus: Potential Genetic and Phenotypic Heterogeneity," <i>Am. J. Hum. Genet.</i> 66:922-932, University of Chicago Press (2000)		
/OC/	NPL9	Strittmatter, W.J., "Apolipoprotein E: High-avidity binding to β -amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease," <i>Proc. Natl. Acad. Sci. USA</i> 90:1977-1981, National Academy of Sciences (1993)		
/OC/	NPL10	Stuart, R.O., <i>et al.</i> , "EEG1, a putative transporter expressed during epithelial organogenesis: comparison with embryonic transporter expression during nephrogenesis," <i>Am. J. Physiol. Renal Physiol.</i> 281:F1148-F1156, American Physiological Society (December 2001)		
Examiner Signature	/Olga Chernyshev/		Date Considered	07/11/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/525,726 (U.S. National Phase of PCT/EP03/09437)
				I.A. Filing Date	August 26, 2003
				First Named Inventor	Heinz VON DER KAMMER
				Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	2	of	3	Attorney Docket Number	2335.0060001/SRL/KPQ

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
/OC/	NPL11	Unger, J.W., "Glial Reaction in Aging and Alzheimer's Disease," <i>Mircosc. Res. Tech.</i> 43:24-28, Wiley-Liss, Inc. (1998)	
/OC/	NPL12	Database Geneseq, Accession No. AAB74706, Lal, P. <i>et al.</i> , (first available and last modified June 2001)	
/OC/	NPL13	Database Geneseq, Accession No. AAM38716, Tang, Y.T. <i>et al.</i> , (first available and last modified October 2001)	
/OC/	NPL14	NCBI Entrez, GenBank Report, Accession No. AF045584, Cole, K.A. <i>et al.</i> , (first available and last modified 1998)	
/OC/	NPL15	NCBI Entrez, GenBank Report, Accession No. AB028927, Fujii, Y. <i>et al.</i> , (first available January 2002 and last modified July 2002)	
/OC/	NPL16	NCBI Entrez, GenBank Report, Accession No. BAB82466, Fujii, Y. <i>et al.</i> , (first available January 2002 and last modified July 2002)	
/OC/	NPL17	NCBI Entrez, GenBank Report, Accession No. XM_165608, NCBI Annotation Project, (first available and last modified May 2002)	
/OC/	NPL18	NCBI Entrez, GenBank Report, Accession No. BC003163, Strausberg, R.L. <i>et al.</i> , (first available February 2001 and last modified February 2004)	
/OC/	NPL19	NCBI Entrez, GenBank Report, Accession No. AL157431, Ottenwaelder, B. <i>et al.</i> , (first available 2000 and last modified February 2005)	
/OC/	NPL20	Database EMBL, Accession No. Q9NSS4 (first available October 2000 and last modified May 2005)	

Examiner Signature	/Olga Chernyshev/	Date Considered	07/11/2007
--------------------	-------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/525,726 (U.S. National Phase of PCT/EP03/09437)
				I.A. Filing Date	August 26, 2003
				First Named Inventor	Heinz VON DER KAMMER
				Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
				Attorney Docket Number	2335.0060001/SRL/KPO
Sheet	3	of	3		

[illegible]

Examiner Signature	/Olga Chernyshev/	Date Considered	07/11/2007
-----------------------	-------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.